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Abstract 
Mesenchymal Stromal Cells (MSC), as advanced therapy products, must satisfy all 
the requirements for human use of medicinal products, aiming to maintain the quality 
and safety of the cells. The MSC manufacturing process for clinical use should 
comply with the principles of Good Manufacturing Practice (GMP). This ensures that 
cell preparations are produced and controlled, from the collection and manipulation of 
raw materials, through the processing of intermediate products, to the quality 
controls, storage, labelling and packaging, and release. 
The objective of this document is to provide the minimal quality requirements for the 
MSC production and its delivery for clinical use, so the safety of the final cell therapy 
product will not be compromised. For this purpose, the document evaluates the most 
important steps of GMP-compliant MSC production: the isolation and expansion 
process; the validation phase of the process, including all quality controls for the 
characterization, functionality, potency and safety of MSCs; the quality control at the 
batch release to guarantee the safety of patient infusion. 
This opinion paper reflects the consensus viewpoint of the authors and scientists 
participating the GISM Working Group*. 
 
 
* GISM Working Group includes the following individual investigators: 
Biagi E, Del Bue M, Frigerio S, Lisini D, Marazzi M, Mareschi K, Nava S, Parolini O, 
Riccobon A, Romagnoli L, Viganò M. 
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Introduction 
Until 2008 gene and cell therapy products were regarded as medicinal products. 
Thereafter, based on the European Regulation 1394/2007, a new classification came 
into place [1]. The Regulation introduced additional provisions to those laid down in 
Directive 2001/83/EC, and a new class of medicines was defined: the tissue 
engineered products. 
For reasons of clarity, complex therapeutic products such as the Advanced Therapy 
Medicinal Products (ATMPs) require a precise legal definition. The Regulation 
defines ATMPs as the gene therapy medicinal products, the somatic cell therapy 
medicinal products and the tissue-engineered products. Each of these products has 
specific pharmacologic, metabolic and immunologic activities and the potential for 
treating a variety of disorders. For these reasons, cellular products for ATMPs, 
prepared on a routine basis, must meet the same stringent conditions required for 
drugs before they are placed on the market. In particular, their activity, efficacy, 
safety and required dose must be defined. Furthermore, they must be manipulated 
according to the Good Manufacturing Practice (GMP) [2], and they require preclinical 
testing in Good Laboratory Practice (GLP) and clinical trials conducted in Good 
Clinical Practice (GCP) before being commercialized [3]. 
In the last decade one cell type in particular, the mesenchymal stromal cells (MSCs), 
have attracted great interest due to the numerous applications proposed for their use 
[4]. Thanks to their intrinsic properties, MSCs represent an attractive candidate for 
clinical applications [5–7]. 
However, as ATMPs, they must satisfy all the above-mentioned requirements. 
Therefore, the quality and safety of the expanded MSCs must be maintained 
throughout their production and quality control cycle, ensuring their safe use in the 
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patient. 
The MSC manufacturing process for clinical use should comply with the principles of 
GMP. This ensures that cell preparations are produced and controlled, from the 
collection and manipulation of raw materials, through the processing of intermediate 
products, to the quality controls, storage, labelling and packaging, and release. 
During the whole production process, critical steps should be known and described. 
A thorough risk analysis during all phases of production and control ensures a final 
product with the expected quality, both for patients and for the Regulatory Authorities 
responsible for controls. 
Nevertheless, MSC-based therapy is different from drug-based therapy in which a 
known chemical entity has known therapeutic effects as well as defined adverse 
events. For this reason, the simple transfer of the same rules “from drug to cell” may 
lead to distortions: criteria to establish bioavailability, biodistribution and excretion 
profiles, potential adverse effects as well as dosage, potency or shelf-life need to be 
adapted and stated. 
There are several papers that discuss standardization of MSC culture for clinical use. 
As reported in the review by Ikebe S., a total of 47 reports, describing MSC-isolation 
methods, were found in literature, published from January 2007 to 2013 [8]. Today, 
numerous MSC preparations from academic institutions and private companies are 
being investigated in nearly 350 clinical trials (>80% of which are phase 1 or 2; 131 
have reached their scheduled completion, and 37 have been reported to be placebo 
controlled). Clinical trials examining the safety and efficacy of MSC have used both 
allogeneic (190) and autologous (150) cells [9].  
Clinical trials exploring MSC therapy have been driven predominately by US 
Companies with proprietary allogeneic MSC preparations such as Osiris’ (now 
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Mesoblast’s) Prochymal. Smaller academic-investigator-driven trials have also been 
conducted in medical centres and academic institutions in Europe, showing the 
safety of allogeneic MSC therapy [10–11]. 
The Guideline on human cell-based medicinal products, issue by EMA on 2008, is a 
useful document for stem cell production for marketing authorization application, 
covering the manufacturing process, quality considerations, process validation and 
clinical considerations [12]. Manufacturing and quality control issues are frequently 
under discussion during the regulatory authorization processes. The recent paper of 
Wuchter summarizes a consensus meeting between researchers, clinicians and 
regulatory experts on standard quality requirements for MSC production [13]. 
However, a practical guideline for standardization of isolation, expansion and 
characterization methods is missing. Moreover, quality controls of starting material, 
intermediate and final products should also be considered, as MSCs must be 
produced in compliance with GMP to ensure reproducibility, efficacy and safety of the 
clinical product. 
Even if the Regulations for biological active substances as GMP Annex 2 [14] can 
help the ATMP’s manufacturer to comply with the GMP requirements, the common 
opinion is that these regulations are still not enough to cover all the Authority 
requirements for safety, efficacy and potency related to the ATMP’s. 
However, a specific step-by-step guideline for MSCs is not available to date. 
In this context, the Italian Group of Mesenchymal Stem Cells (Gruppo Italiano 
Staminali Mesenchimali – GISM), that aim to promote changes and informations 
among researchers, in particular on clinical application, in this opinion paper, 
proposes the minimal quality requirements for the production and delivery of MSCs 
for clinical use. This paper can be considered a proposed tentative guideline that 
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provides indications for standardization and optimization of production time and costs 
according to the GMP requirements, without compromising the safety of the final cell 
therapy product. 
The aim of this document is to clarify the critical control points that must be 
considered during the process of expansion and release of MSC as ATMPs. For this 
purpose, the document will evaluate the most important steps of GMP production for 
the application of clinical trials with MSCs. These steps include: 1) the isolation, 
identification and expansion process; 2) the validation phase of the process, 
including all quality controls for MSC characterization, functionality, potency and 
safety; 3) the quality control at the batch release to guarantee the safety of patient 
infusion. This last step is also applied to products that must be cryopreserved, 
assuming that the cryopreservation process has been validated during the validation 
phase. The thawing phase is not covered by this document. 
 
Isolation and expansion of mesenchymal stromal cells (MSCs) 
The term “mesenchymal stem cells” initially referred to multilineage progenitor cells 
isolated and culture-expanded from human adult bone marrow (BM), that once in 
culture display a heterogeneous morphology and are capable of several 
subpopulations. Horwitz and the International Society for Cellular Therapy (ISCT) 
[15] better defined them as “mesenchymal stromal cells”. 
Although BM is still the most common source of MSCs, during the last two decades 
alternative and more accessible tissue sources of MSCs have been identified. For 
instance, MSCs have been isolated from tissues, such as fat, deciduous teeth, 
placenta and umbilical cord blood, showing comparable features to BM-derived cells 
[16-17]. In particular, fresh umbilical cord blood (UCB) is the third common source for 
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isolating MSCs for clinical use, but the success rate in isolating and further 
expanding MSCs depends on the volume of blood collected, the cell content, and the 
time between collection and processing [18]. Also MSCs isolated from Wharton’s jelly 
(WJ), are able to maintain their self-renewal capacity in vitro for a long period of time, 
showing a higher pluripotency capacity as compared to BM-MSCs [19]. 
MSCs have been isolated from several different placenta regions, although the 
isolation of cells from this region carries a risk of contamination with maternal 
decidual cells. Placental MSCs exhibit plastic adherence and fibroblast-like 
morphology in culture, and a phenotype in line to ISCT Guidelines [20]. They are able 
to undergo multilineage differentiation, and even have the capacity to differentiate 
across germinal boundaries outside of their specific lineage [16]. 
Adipose-derived stem cells (ASCs), if compared to BM MSCs, have been found to be 
genetically and morphologically more stable in culture [21], to have lower 
senescence ratio [22], higher proliferative capacity [21], to be able to retain 
differentiation potential for a longer period in culture [21], to be a more efficient 
support to hematopoiesis (both in vitro and in vivo) [23] and to have minor 
immunophenotypical differences [24]. These in vitro properties have allowed this 
attractive cell populations to be tested in clinical studies for the treatment of a variety 
of clinical conditions, including Crohn’s disease , end-stage coronary disease, acute 
myocardial ischemia, femoral head osteonecrosis, calvarial defects, breast 
reconstruction, facial lipoatrophy [25]. 
For the purpose of this paper, the intended source of MSCs, for which there are 
scientifically proven clinical applications, are bone marrow, umbilical cord blood, 
adipose tissue, placenta (www.clinicaltrials.gov). 
All the reagents and materials used during the manufacturing of the cell-based 
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medicinal products should be well defined and controlled, the suppliers should be 
validated, and all the batches received should be approved by the Quality Control 
Unit of the manufacturing site, on the basis of specifications and quality control tests. 
The cells and tissues used as raw material to produce cell-based medicinal products 
must comply with the Directive 2004/23/EC, Directive 2006/17/EC and Directive 
2006/86/EC on the donation, procurement and testing of human tissues and cells 
[26-27]. In particular, the Annex 1 of the Directive 2006/17/EC defines the selection 
criteria for donors, and the Annex 2 defines the laboratory test required for donors. 
So far, the application of GMP reagent in MSC ex vivo culture has been limited by 
the fact that only few are commercial availability, such as PBS, cell culture media and 
trypsin. The introduction of closed systems for the isolation without density gradient 
separation, improved the generation of safe clinical protocols. In the case of BM and 
peripheral blood stem-cell collection, blood samples must be taken for testing within 
30 days prior to donation (table 1). 
In the case that Bovine Serum is used in the manufacturing of cell-based medicinal 
products, the viral risk and the risk of transmitting animal spongiform encephalopathy 
agents must be carefully evaluated according to the EMA Guidance CHMP/BWP/ 
457920/2012 [28]. In order to comply with the Regulation requirements, the 
manufacturer of FBS should provide the serum user with the EDQM certificate of 
suitability of the Foetal Calf Serum, and ensure the safety with regard to the risk of 
transmitting animal agents via veterinary medicinal products [29]. 
Several different methods for isolating MSCs have been described. The identification 
of “optimal” conditions is important in order to identify a standard procedure for 
clinical use. No significant differences among Ficoll, Percoll or whole BM separation 
methods have been described in terms of morphology, growth rate at the 1st 
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passage, cumulative population doubling (CPD), immunophenotype or differentiative 
potential. However, direct selection of MSCs from BM cells by adhesion to culture 
plastic is a more advantageous method compared to MSCs obtained by gradient 
separation [30], and results in a significantly higher level of HLA-DR [31]. Human 
platelet lysate (HPL) is being established as a safe and efficient MSC culture 
supplement for robust MSC cultivation, thus offering certain advantages as a 
potential FBS substitute [32-33]. 
However, as the use of human-derived blood materials leads to immunologic and 
infectious risks, the application of the Pathogen Inactivation is safe and the 
inactivated HPL represents a good, GMP-compliant alternative to FBS [34]. This is 
because it reduces manipulation and haematopoietic contamination (cellular growth) 
and represents a good procedure for MSC expansion for clinical use [35-36]. The 
gradient separation cannot be applied to those tissues characterized by a solid 
matrix, such as fat and placenta, for which the first step to isolate MSCs is the 
enzymatic digestion. After this, the direct selection of MSCs can be achieved by 
plastic adhesion to the culture surface. Another important parameter to be 
considered is the cells’ seeding density, which has been demonstrated to be 
important for the expansion of MSCs in culture. Recent studies showed that directly 
plated BM offers a more advantageous method in terms of CFU-F number, minimal 
manipulation, hematopoietic contamination, and cellular growth, showing a minor 
hematopoietic contamination at the 1st passage with whole BM rather than with 
Percoll or Ficoll [30, 35-36]. An initial plating density between 10000 and 100000 
cells/cm2, using flasks for large scale cell culture, significantly improves the 
expansion growth, providing a high number of cells from a small quantity of BM [30]. 
For the purpose of this paper, the validation of the better culture condition, 
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considering the medium, the use of animal-derived supplements, the plastic, and the 
density and number of passages, should be carried out on at least three 
representative MSC samples. 
 
Quality control for validation of MSC production 
The quality and safety of MSCs must be maintained throughout their production and 
quality control cycle, ensuring their final use in the patient. According to International 
Conference on Harmonization Q2 (ICH Q2) Guidelines [37] and the European (EU) 
Pharmacopoeia [38], the quality control process should be validated to confirm that 
the analytical procedure employed for a specific test is suitable for its intended use. 
The process should follow a validation protocol, also considering instruments, 
supplies and reagents, and defining roles and responsibilities of each step [39]. A 
useful scheme of manufacturing and quality control processes of MSC production as 
a cell therapy medicinal product is represented by Galvez [40]. In figure 1 two flow-
charts on validation and production processes are represented. A validation protocol 
on a minimum of three expansion procedures should be implemented to standardize 
the best culture condition and to demonstrate the safety and feasibility of the 
production protocol. 
Results from method validation can be used to judge the quality, reliability and 
consistency of analytical results [39].  
The elements of the analytical method requiring proof through validation as contained 
in the ICH Q2A guidelines are specificity, accuracy, precision, repeatability, linearity 
and range, as shown in table 2.  
 
Identity 
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The International Society for Cellular Therapy (ISCT) proposed three minimal criteria 
to identify BMSCs: the adherence to plastic; the expression of a specific surface 
antigen (positivity for CD105, CD73,CD90 and negativity for CD45, CD34, CD14 or 
CD11b, CD79a or CD19 and HLA class II); the ability to differentiate into osteoblasts, 
adipocytes or chondroblasts under standard in vitro  culture conditions [41]. These 
criteria can be also applied to MSCs deriving from other tissue sources, although 
their immunophneotype can be slightly different, above all in the early phases of 
culture” [42]. Plastic adherent MSCs are typically visible 5-7 days after plating, 
appearing at microscopy as fibroblastoid cells with a heterogeneous shape, also 
including endothelial-like cells. However, during expansion, the adherent cells 
become less heterogeneous, and fibroblast-like cells become predominant. 
MSCs surface marker expression may be influenced by the different source of cells 
and by the method of isolation. Although human MSCs are also positive for several 
markers, including embryonic stem cell markers, such as Oct-4, Rex-1, and Sox-2 [4] 
for the purpose of this guideline, the minimal criteria to identify MSCs are the 
following: positivity for CD105, CD73, CD90 and negativity for CD45, CD34, CD14. In 
particular, the phenotype of MSCs should at least show positive expression (>90%) 
for CD105, CD73, CD90, and negative expression (<5%) for CD45, CD34 and CD14. 
The capacity to differentiate into osteoblasts, adipocytes, and chondrocytes under 
standard in vitro differentiating conditions is still the most valid demonstration of MSC 
multipotentency  [41]. The evidence of osteogenic differentiation should be 
demonstrated by alkaline phosphatase activity and calcium deposition staining (Van 
Kossa staining or Alizarin staining). Adipogenic differentiation should be 
demonstrated through the morphological appearance of lipid droplets stained by Oil 
Red O staining. Chondrogenic differentiation can be evaluated by culturing MSCs in 
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complete commercial chondrogenic medium as cellular aggregates floating freely in 
suspension culture; after inclusion in paraffin, the pellet could be stained with Alcian 
Blue to identify the presence of hyaluronic acid and sialomucin. 
The multipotent capacity should be demonstrated for all three of the differentiative 
lineages. 
MSCs are a promising tool for cell therapies also for their immunomodulant 
proprieties, thanks to their paracrine production of trophic factors together with their 
broad immune modulatory and anti-inflammatory functions [43]. 
The recent paper of Menard and Krampera [44] suggested some reproducible 
immunological assays to quantify the immune-modulatory properties of MSCs 
produced according to GMP. However, these analysis are recommended in the 
validation (or in pre-clinical) phase, but not mandatory for the release of MSC. 
 
Growth characteristics 
The cellular expansion growth rate of MSCs should be evaluated by counting the cell 
at each passage and expressed in terms of CPD using the formula log N/ log 2, 
where N is the cell number of the confluent monolayer divided by the initial number of 
cells seeded [45].  
For clinical safety issues, the expansion should not exceed 4 passages, in an attempt 
to minimize the administration of senescent cells. 
 
Sterility 
For microbiological control, the sterility should be evaluated at each passage on a 
representative sample of the products, containing cells (EuPh 2.6.27). Due to the 
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small volume of the cell-based medicinal products, the analysis is commonly 
performed on the supernatant. 
- Bacteriology. For microbiological control, the samples could be tested through 
rapid microbiology test according to EuPh 2.6.27 [38, 46]. 
- LAL test. LAL assay should be used as a quantitative method to detect Gram-
derived endotoxin in a solution according to EuPh 2.6.14 [38]. 
- Mycoplasma. Any mycoplasma contamination could be detected through a 
semi-quantitative PCR reaction. In alternative, culture methods, or indicator 
cell culture technique have to be performed. All techniques need to be 
validated and must be performed according to current European 
Pharmacopoeia chapter 2.6.7 [38]. 
 
Tumorigenesis 
Although tumour formation during the validation process has not been reported in 
ongoing clinical trials using MSCs [47], tumorigenesis should be tested during 
validation. 
For the purpose of this guideline, the valid methods to exclude the potential 
tumorigenicity are as follows: 
- Assessment of telomerase activity, considering that it has been documented 
that non-malignant human MSCs display a low/undetectable level of 
telomerase acitivity;  
- Soft agar test, with a commercial cell line as the positive control or with the in 
vivo test carried out on suitable animals as reported in European 
Pharmacopoeia 5.2.3 [38]. 
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Karyotype 
In order to demonstrate that the expansion method maintain the genomic 
stability during the in vitro culture period, the karyotype analysis should be 
performed. Some studies reported that human MSCs retained chromosomal stability 
following long-term culture in vitro [47-48].  Tarte showed that MSCs with or without 
chromosomal alterations, became senescent, without evidence of transformation 
either in vitro or in vivo, assuming that karyotyping and FISH results are not 
informative and are thus not adequate controls for the release of MSCs for clinical 
uses [49]. The analysis of Ben-David at colleagues [50], reveals that MSCs have a 
4% probability of acquiring chromosomal abnormalities. However, this study has 
been argued by Sensebè’s group [51]. 
Recently, Capelli’s group performed a large study, by conventional karyotype 
analysis, on 92 clinical grade BM-derived MSCs, showed the presence of only 
spontaneous non-clonal anomalies, assuming that the lack of clonal aberrations or 
the presence of non-clonal anomalies on 10% of the analysed metaphases should be 
set as the release criteria for MSCs distribution [52]. This is on line with the Cell 
Products Working Party, in which, it has been proposed, that a karyotype or FISH 
analysis should be necessary, at batch release, only in cases in which recurrent 
chromosomal anomalies are found [53]. 
The demonstration of the absence of genetic instability by karyotype analysis should 
be assessed by molecular [54] or conventional methods (G banding). At least 20 
metaphases should be analysed, and in the presence of aberrations, 20 more 
metaphases are requested, as defined by the General Guidelines and Quality 
Assurance for Cytogenetics [47, 55-56]. The karyotyping analysis would be sufficient 
as a release test with the exclusion of two identical abnormal metaphases on 20 
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metaphases analysed (10%) [53], comparing the final batch to the donor/patient 
karyotype status.  
 
Quality control in-process for MSCs 
For identity, morphology, immunophenotype and growth characteristics MSCs can be 
evaluated as described for the validation phase. 
For microbiological in-process control, the sterility should be evaluated on cells and 
on supernatant samples, by rapid microbiology methods (EuPh 2.6.27) or by 
classical methods (EuPh 2.6.1) by a GMP approved Quality Control laboratory [40].  
The quality control analysis and GMP batch release testing, is part of the 
manufacturing process. For this reason, these tests should be carried out in the 
same GMP facility, in a dedicated and validated laboratory or as outsource in 
laboratories providing this service in compliance with GMPs. 
 
Quality control at batch release for MSCs 
At batch release, MSCs should be analysed for morphology and immunophenotype, 
as previously described. In addition, the following tests should be carried out. 
 
Identity 
Viability could be evaluated by Trypan Blue exclusion cell counting at microscopy, or 
by Iodure Propidium exclusion with cytofluorimetric analysis. Both the methods 
should be validated according to ICH Q2 guidelines. The final batch should have a 
viability > 90%. 
Cross-contamination evaluation, by the analysis of Short Tandem Repeat (STR) DNA 
profiling to assess the identity of the final product to exclude a cross-contamination 
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should be assessed only in case it is necessary to share spaces and instruments for 
the processing of different donors. 
 
Sterility 
Bacteriology, LAL test and mycoplasma should be analyzed as previously described. 
For microbiological control, the sterility should be evaluated on cells and on 
supernatant samples, according to current European Pharmacopoeia by an 
accredited laboratory. 
The rapid microbiology methods applied to ATMP’s are commonly methods to 
substitute time consuming testing as Sterility testing and Mycoplasma testing. These 
rapid tests are described in the European Pharmacopoeia and the methods for 
validation are also described in details. In particular, the chapter EuPh 2.6.27 
“Microbiological control of cellular products” recommends the rapid method for the 
release of the ATMP’s in order to evaluate the sterility post-inoculation in a shorter 
time in comparison to the colture-based methods. The Mycoplasma evaluation on 
ATMP’s should be performed according to the chapter EuPh 2.6.7 “Mycoplasmas” 
describing both culture methods (Cultural and Indicator cells culture method) and 
rapid methods as NAT methods qualitative and quantitative. 
Since the expanded cells are Medicinal Products, the tools to assess how and which 
adventitious agents can contaminate the colture should be defined according to the 
principles of the Quality Risk Management as referred to the ICH Q9 Guideline [57]. 
In particular, a Failure Mode Effect Analysis (FMEA) tool can be suitable to evaluate 
the hazardous agents considering the potential source of contamination such as the 
ancillary material for manufacturing, the adventitious from the manufacturing 
operators etc.  
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In the United States Pharmacopoeia, chapter 1050, Viral Safety Evaluation of 
Biotechnology Products Derived from Cell Lines of Human or Animal Origin [58], an 
exhaustive approach to assess the viral contamination from cell based medicinal 
products is presented and can be useful to use the suggested sources of 
contamination also evaluating bacterial, endototoxin, mycoplasma and TSE agents 
contamination. In particular, the evaluation of the risk associated to the TSE agents 
contamination is well described in the EMA Note for guidance on minimising the risk 
of transmitting animal spongiform encephalopathy agents via human and veterinary 
medicinal products (EMA/410/01 rev.3) [59]. 
The evaluation of infections of extraneous agents must be performed either on cell 
batches used as the feeder-layer or on the final product. One of the following tests 
must be performed with the aim to detect adventitious viruses: 
- Inoculation on selected cell lines; 
- Detection of retroviruses; 
- Mice inoculation (test in animals); 
- Chicken embryos inoculation (test in eggs); 
- Nucleic acid amplification test (NAT). 
All of the above reported tests must be performed according to current European 
Pharmacopoeia (chapters 2.6.16; 5.2.3). 
Regarding the final product of MSCs, due to the small available amount of cells, only 
the inoculation on selected cell lines and retrovirus detection test, should be 
performed. 
It must be outlined that animal reagents such as fetal bovine serum used in cell 
amplification must be tested with the aim to detect contaminants as reported by the 
EMA document EMA/CHMP/BWP/457920/2012 [28]. 
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Similarly, reagents of swine origin-like proteolytic enzymes have to tested by NAT 
techniques or by inoculation in susceptible cell cultures to detect virus contamination. 
Mycoplasma detection has to be carried out by the methods previously reported. 
A summary panel of required quality controls is shown in table 3. 
 
Batch control sample 
A sizable aliquot of the final batch should be cryopreserved as a backup in order to 
further analyze the cells in case of a clinical need. 
 
Conclusion 
MSC production according to GMP requirements is an important issue that has 
emerged in recent years. Currently there is no consensus on quality standards for the 
production of MSC for clinical application. In this paper the GISM Working Group has 
identified the minimal quality criteria for MSCs at different production stages.  
As the recent work of a group of German researchers pointed out the manufacturing 
and quality control issues [13], we hope that our work could be a significant first step 
forward the awareness of the Regulatory Authority that a wider agreement on this 
matter is the needing. 
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Figure 1. Flow chart representing the workflow and the steps of the validation phase 
(panel A), and the production process (panel B) of mesenchymal stromal cell as a 
cell therapy medicinal product. 
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Table 1. Biological tests required for all donors as a minimum requirement. 
HIV 1 and 2 Anti-HIV-1,2 
Hepatitis C Anti-HCV-Ab 
HCV-RNA/HIV1-RNA/HBV-DNA TriNAT 
Hepatitis B HBsAg 
Anti HBc 
Syphilis A validated testing algorithm must be applied to exclude the 
presence of active infection with Treponema pallidum. A non-
reactive test, specific or non-specific, can allow tissues and 
cells to be released. A donor whose specimen tests reactive on 
a Treponema-specific test will require a thorough risk 
assessment to determine eligibility for clinical use. 
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Table 2. Types of Analytical Procedures to be validated and typical validation 
characteristics to be considered (24).  Signifies that this characteristic is normally 
evaluated. 
Type of analytical 
procedure 
IDENTIFICATION TESTING FOR IMPURITIES ASSAY 
QUANTITATION LIMIT 
CHARACTERISTICS     
ACCURACY       
PRECISION      
REPEATABILITY       
INTER PRECISION       
SPECIFICITY         
DETECTION LIMIT      
QUANTITATION LIMIT      
LINEARITY       
RANGE       
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Table 3. Summary of required quality controls on MSCs. CPD: Cumulative 
population doubling; LAL: Limulus amebocyte lysate; *: according to European 
Pharmacopoeia. 
 VALIDATION 
 
IN PROCESS 
 
AT BATCH RELEASE 
IDENTITY MORPHOLOGY MORPHOLOGY MORPHOLOGY 
 IMMUNOPHENOTYPE IMMUNOPHENOTYPE IMMUNOPHENOTYPE 
 DIFFERENTIATIVE 
POTENTIAL 
  
 VIABILITY  VIABILITY 
   CROSS-CONTAMINATION 
GROWTH CPD CPD CPD 
STERILITY BACTERIOLOGY TEST BACTERIOLOGY TEST BACTERIOLOGY TEST* 
 LAL TEST  LAL TEST* 
 MYCOPLASMA TEST  MYCOPLASMA TEST* 
 ADVENTITIOUS 
VIRUSES* 
 ADVENTITIOUS VIRUSES* 
TUMORIGENESIS TELOMERASE  
IN VITRO ASSAY 
IN VIVO ASSAY 
  
 KARYOTYPE  KARYOTYPE 
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